Rethinking Cardiovascular Prevention: Cost-Effective Cholesterol Lowering for Statin-Intolerant Patients in Australia and the UK
{{output}}
Background: Approximately 1 in 11 people are intolerant to statins. There have been no studies evaluating the cost-effectiveness of early intervention for primary prevention of cardiovascular disease (CVD) with three non-statin d... ...
